Low-dose radiation with immunotherapy and chemo for advanced rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of low-dose radiation, an immunotherapy drug called pucotenlimab, and chemotherapy for locally advanced rectal cancer that has not spread. The goal is to see if adding radiation helps shrink the tumor more effectively before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have rectal cancer that is locally advanced (not spread to distant organs).
- Your tumor is within 10 cm of the anal verge (the opening).
- Your cancer has a normal DNA repair function (pMMR or MSS).
- You have not had radiation to the pelvis or abdomen before.
- You have not had prior immunotherapy or chemotherapy for this cancer.
- You have adequate organ function and no severe autoimmune disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding an immunotherapy drug (pucotenlimab) to standard chemotherapy (CAPOX) before surgery helps treat locally advanced rectal cancer better. The goal is to shrink tumors and improve survival while preserving bowel function when possible.
This trial tests a shorter radiation course combined with two chemotherapy drugs and an immunotherapy drug for people with locally advanced rectal cancer that is microsatellite stable. The goal is to shrink the tumor before surgery, which may improve outcomes with fewer side effects.
This trial tests a new combination for locally advanced rectal cancer: adding a cholesterol-lowering drug plus an immunotherapy drug to the standard chemotherapy and radiation before surgery. The goal is to see if this combination shrinks tumors more effectively and improves outcomes.
This trial tests adding an immunotherapy drug (pucotenlimab) to standard radiation and chemotherapy before surgery for locally advanced rectal cancer. The goal is to see if this combination can shrink the tumor more effectively and improve outcomes.
This trial tests a combination of short-course radiation, internal radiation (brachytherapy), and several drugs to shrink rectal cancer before surgery. The goal is to improve outcomes and potentially avoid more extensive surgery.
This trial tests a combination of radiation, chemotherapy (CAPOX), and immunotherapy (iparomlimab and tuvonralimab) given before surgery for locally advanced rectal cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
Hear when a new Colorectal Cancer (CRC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.